Menopause associated with increased prevalence of cardiovascular autonomic neuropathy in women with diabetes: this study

Published Date: 02 Mar 2023

Spain: A recent study showed an increase in subclinical autonomic neuropathy (CAN) in women aged 1...

Read Full News

Latest News

New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity

New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity

8 Endocrinology Headlines You Missed in Q3 2026

8 Endocrinology Headlines You Missed in Q3 2026

Investigational Rapid-Acting U500 Insulin Maintains Efficacy Regardless of BMI Thomas Pieber, MD

Thomas Pieber, MD, discusses a recent phase 1 trial investigating AT278’s efficacy in patients with T2D and obesity compared to other fast-acting insulins.

Converting Basal Insulin Patients to Insulin Icodec Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss switching patients from basal insulin to Awiqli.

Insulin Icodec Dosing Strategies for Type 2 Diabetes Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the commercial release of insulin icodec.

EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes

EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Latest News

New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity

8 Endocrinology Headlines You Missed in Q3 2026

Thomas Pieber, MD, discusses a recent phase 1 trial investigating AT278’s efficacy in patients with T2D and obesity compared to other fast-acting insulins.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss switching patients from basal insulin to Awiqli.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the commercial release of insulin icodec.

EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes

News All Time

Medically Tailored Groceries Improve Blood Sugar Control, Nutrition in T2D Ryan Livingston

A recent study from Kaiser Permanente has indicated substantial HbA1c improvements among patients receiving food-based support.

5 Endocrinology Headlines You Missed in July 2026 Ryan Livingston

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

500,000 Patients With Diabetes May Lose Healthcare Under New Medicaid Legislation Ryan Livingston

Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.

Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline data from the TRIUMPH-3 trial of retatrutide.

Ascendis Reports 78-Week Data From COACH Trial for Achondroplasia Ryan Livingston

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the topline results of the TRIUMPH-2 trial of retatrutide.

Secret Shopper Study Reveals GLP-1 Telehealth Gaps Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the risks of ordering GLP-1 RAs online.

Insulin Icodec Now Available for Type 2 Diabetes in US Ryan Livingston

Novo Nordisk's once-weekly insulin icodec-abae (Awiqli) has launched nationwide for adults with type 2 diabetes.

Diabetes Dialogue: Tech, Screening, and Care Highlights from ADCES 2026 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

Diabetes Dialogue hosts recap ADCES26 highlights on insulin delivery tech, CKM care, C-peptide science, ketone monitoring, and hypercortisolism screening.

Tirzepatide Demonstrates Cardioprotective Effects in T2D With ASCVD Ryan Livingston

In a trial comparing tirzepatide initiation with sitagliptin, the GLP-1/glucose dual agonist displayed greater reductions in major cardiovascular events.

VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes Marc P. Bonaca, MD, MPH

The phase 3 trial of evolocumab showed cardioprotective effects in patients without prior MI or stroke, regardless of qualifying atherosclerosis or background therapy.

Continuous Ketone Monitoring May Guide SGLT2i Use in T1D Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the promise of continuous ketone monitoring in T1D.

The HCPFive: Top News for Healthcare Providers from the Week of 08/16 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including a new lerodalcibep FDA approval and phase 3 avexitide data in post-bariatric hypoglycemia.

Avexitide Reduces Hypoglycemic Events in Phase 3 LUCIDITY Trial for PBH Ryan Livingston

The phase 3 trial showed a 55% reduction in Level 2 and Level 3 hypoglycemic events versus placebo, meeting all secondary endpoints.

New Patch Pump Options Highlighted at ADCES 2026 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss new insulin pump technology presented at ADCES 2026.

FDA Clears Beta Bionics' Mint Insulin Patch Pump for Diabetes Ryan Livingston

Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.

Recommended News For You

SBRT May Beat Brachytherapy in Prostate Cancer

Combination Treatment May Improve Multiple Myeloma Outcomes

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

3D virtual staining technology enables non-invasive observation of cancer tissue

Fear of hair loss might cause some to reject cancer treatment

Nonmelanoma skin cancer has been linked to occupational exposure to solar UVR.

Research suggests peer support may lower depression, stress among cancer patients in low-resource settings

Recommended Articles For You

Blood Aging Profiles in Wellness Screening: Clinical Implications and Emerging Evidence 

Precision Oncology: Tailoring Cancer Treatment for the Individual 

Oncology Trials Roadmap: From Drug Discovery to Delivery and Patient Access 

Evolving Cancer Treatments: Innovations, Success Rates, and Mechanisms 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

MRI can save rectal cancer patients from surgery, study suggests

2.

When Healthcare Chatbots Fall Short of Human Connection

3.

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

4.

Antibiotic Use in Hospice Linked to Higher Mortality Risk

5.

Two Survival Wins in NSCLC With Bispecific Seeking Worldwide Status

1.

Multiple Primary Lung Cancer: Multidisciplinary Advances in Diagnosis and Care

2.

Genetic Screening: A Game Changer in Cancer Prevention

3.

All You Need to Know About Mesna: The Ultimate Guide

4.

Unveiling the Hidden Causes of Anemia: A Comprehensive Look at a Common Condition

5.

Targeting BRAF V600E in mCRC: FOLFOX, Cetuximab & Encorafenib Strategies

1.

International Conference on Oncology, Cardiology and Critical Care Policy

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Cancer Nursing and Hematology Support

1.

Innovations in Hematology

2.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective

3.

Should We Use DARA Up Front As First-Line Therapy in MM? - Part II

4.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

5.

Blood Clotting Disorders Explained

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot